Table 2.

Baseline characteristics of patients enrolled in the included randomised clinical trials

	CAT		AMIOVIRT		DEFINITE		COMPANION			SCD-HeFT			DANISH
	MT	ICD	MT	ICD	MT	ICD	MT	CRTP	CRTD	Placebo	Amio	ICD	MT	ICD
Enrolled patients (n)	54	50	52	51	229	229	308	617	595	847	845	829	560	556
Patient characteristics
Age, years	52	52	60	58	58	58	68	67	66	60	60	60	63	64
Male	77	86	74	67	70	73	69	67	67	77	76	77	72	73
AF	11	20	n. r.	n. r.	26	23	n. r.	n. r.	n. r.	14	16	17	20	24
niCMP	100	100	100	100	100	100	41	46	45	47	50	48	100	100
Duration of HF, years	2.5	3	1.8	2.2	3.3	2.4	4.9	n. r.	4.4	n. r.	n. r.	n. r.	1.5	1.7
LVEF, %	25	24	23	22	22	21	22	20	22	25	25	24	25	25
NYHA class
– I			13	18	18	25
– II	64	67	63	64	61	54				70	71	68	54	53
– III	36	33	24	16	21	21	82	87	86	30	29	32	46	47
QRS duration, ms	114	102	n. r.	n. r.	116	115	158	160	160	n. r.	n. r.	n. r.	145	146
CRT	0	0	0	0	0	0	0	100	100	0	0	0	57	58
Pharmacological therapy
Amiodarone	n. r.	n. r.	100	0	7	4	55	n. r.	55	n. r.	100	n. r.	6	6
Betablocker	4	4	50	53	84	86	66	68	68	69	69	69	92	92
ACE/ARB	98	94	81	90	96	97	89	89	90	98	97	94	97	96
MRA	n. r.	n. r.	19	20	n. r.	n. r.	55	53	55	n. r.	n. r.	20	57	59

Continuous data are presented as mean or median and categorical data as percentage

ACE angiotensin-converting enzyme, AF atrial fibrillation, ARB angiotensin receptor blocker, CRT cardiac resynchronisation therapy, CRT‑D cardiac resynchronisation defibrillator, CRT‑P cardiac resynchronisation pacemaker, HF heart failure, ICD implantable cardioverter-defibrillator, LVEF left ventricular ejection fraction, MT medical therapy, niCMP non-ischaemic cardiomyopathy, n. r. not reported, NYHA New York Heart Association, OMT optimal medical therapy